Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
122
Recruiting Now
122
Top Conditions in Phase 2 / Phase 3
Gastric Cancer (2) Pancreatic Ductal Adenocarcinoma (2) Breast Cancer (2) Non-Squamous Non-Small Cell Lung Cancer (2) Primary Central Nervous System Lymphoma (2) Multiple Myeloma (2) HCC (2) Heart Failure (2) Acute Myeloid Leukemia (2) Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (1)
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT07502118 Phase 2, Phase 3
Recruiting
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (...
Condition
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment
40 pts
Location
Turkey (Türkiye)
Sponsor
Health Institutes of Turkey
NCT07354516 Phase 2, Phase 3
Recruiting
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Condition
OAG - Open-Angle Glaucoma
Enrollment
60 pts
Location
United States
Sponsor
Qlaris Bio, Inc.
NCT05327114 Phase 2, Phase 3
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory De...
Condition
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment
201 pts
Location
United States, Argentina, Australia
Sponsor
Janssen Research & Development
NCT06782412 Phase 2, Phase 3
Recruiting
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-assoc...
Condition
Oesophageal Cancer
Enrollment
109 pts
Location
Belgium
Sponsor
KU Leuven
NCT07199504 Phase 2, Phase 3
Recruiting
A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia Wit...
Condition
Restless Leg Syndrome Due to Uraemia
Enrollment
80 pts
Location
China
Sponsor
Yunfeng Xia
NCT05670847 Phase 2, Phase 3
Recruiting
Exogenous Ketone Esters for Drug Resistant Epilepsy
Condition
Drug Resistant Epilepsy
Enrollment
60 pts
Location
Egypt
Sponsor
Sohag University
NCT03463252 Phase 2, Phase 3
Recruiting
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Condition
Endometrial Cancer
Enrollment
224 pts
Location
China
Sponsor
West China Second University H
NCT06014801 Phase 2, Phase 3
Recruiting
Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for ...
Condition
Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
Enrollment
400 pts
Location
Japan
Sponsor
Jikei University School of Med
NCT04803539 Phase 2, Phase 3
Recruiting
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Thera...
Condition
Breast Cancer
Enrollment
260 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital
NCT06427707 Phase 2, Phase 3
Recruiting
The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infu...
Condition
Intraoperative Bleeding
Enrollment
90 pts
Location
Egypt
Sponsor
Ain Shams University
NCT07202065 Phase 2, Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing...
Condition
Myeloma
Enrollment
900 pts
Location
Australia
Sponsor
Monash University
NCT07086755 Phase 2, Phase 3
Recruiting
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome...
Condition
Nonintubated Acute Respiratory Distress Syndrome (ARDS)
Enrollment
1,100 pts
Location
United States
Sponsor
Bentley J. Bobrow
NCT06972511 Phase 2, Phase 3
Recruiting
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
Condition
Oligometastatic Prostate Cancer
Enrollment
120 pts
Location
China
Sponsor
RenJi Hospital
NCT06453304 Phase 2, Phase 3
Recruiting
Effectiveness of Glycyrrhizin as Intracanal Medication in Root Canal Disinfectio...
Condition
Intracanal Medication
Enrollment
36 pts
Location
Egypt
Sponsor
Mansoura University
NCT05786599 Phase 2, Phase 3
Recruiting
Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy
Condition
Chemotherapy-induced Peripheral Neuropathy
Enrollment
50 pts
Location
Canada
Sponsor
University of British Columbia
NCT06756152 Phase 2, Phase 3
Recruiting
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedoli...
Condition
Biphenotypic Acute Leukemia
Enrollment
50 pts
Location
Russia
Sponsor
Federal Research Institute of
NCT06764238 Phase 2, Phase 3
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Condition
Acute Lymphoblastic Leukemia ALL
Enrollment
1,800 pts
Location
China, Hong Kong
Sponsor
Institute of Hematology & Bloo
NCT06417008 Phase 2, Phase 3
Recruiting
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non...
Condition
Non-Squamous Non-Small Cell Lung Cancer
Enrollment
1,080 pts
Location
China
Sponsor
Hansoh BioMedical R&D Company
NCT02836158 Phase 2, Phase 3
Recruiting
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Pa...
Condition
Primary Central Nervous System Lymphoma
Enrollment
100 pts
Location
China
Sponsor
Navy General Hospital, Beijing
NCT07373782 Phase 2, Phase 3
Recruiting
Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cance...
Condition
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Enrollment
53 pts
Location
Belgium
Sponsor
Universitaire Ziekenhuizen KU
NCT06112340 Phase 2, Phase 3
Recruiting
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to ...
Condition
Thyroid Eye Disease
Enrollment
75 pts
Location
United States
Sponsor
Sling Therapeutics, Inc.
NCT07487818 Phase 2, Phase 3
Recruiting
A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation
Condition
Smoking Cessation
Enrollment
150 pts
Location
United States
Sponsor
Mayo Clinic
NCT06862596 Phase 2, Phase 3
Recruiting
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atroph...
Condition
Spinal and Bulbar Muscular Atrophy
Enrollment
68 pts
Location
Japan
Sponsor
Masahisa Katsuno
NCT07592273 Phase 2, Phase 3
Recruiting
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Particip...
Condition
Diabetic Retinopathy
Enrollment
576 pts
Location
United States, Puerto Rico
Sponsor
AbbVie
NCT04924322 Phase 2, Phase 3
Recruiting
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
Condition
Deep Venous Thrombosis
Enrollment
258 pts
Location
United States
Sponsor
Yale University
Page 1 of 5 — 122 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology